NCT02415842View on ClinicalTrials.gov

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

CompletedOBSERVATIONAL
Enrollment

414

Participants

Timeline

Start Date

October 26, 2015

Primary Completion Date

February 16, 2018

Study Completion Date

February 16, 2018

Conditions
Immunologic Tests
Interventions
OTHER

Serum samples

The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Trial Locations (1)

10029

GSK Investigational Site, New York

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT02415842 - A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines | Biotech Hunter | Biotech Hunter